Aurora Kinase Modulators for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are limited in effectiveness due to unregulated cell proliferation, particularly in cancers where Aurora kinase is overexpressed, as existing therapies fail to adequately target and inhibit these kinases effectively.
Innovation Solution
Development of new compounds, defined by specific chemical formulas (I, II, III), which exhibit Aurora kinase modulatory activity, particularly inhibitory activity, for use in pharmaceutical compositions to treat cancer and related disorders by targeting Aurora kinase enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cancer treatments are used, then treatment options are available, but effectiveness is limited due to inability to adequately inhibit Aurora kinase
Solution Approach 1:
The patent modifies the chemical structure of Aurora kinase inhibitors by changing parameters such as substituting aromatic rings with heteroaromatic rings, adjusting substituent positions, and modifying molecular weight and lipophilicity. These parameter changes optimize the compounds' binding affinity and selectivity for Aurora kinase, thereby improving treatment effectiveness while reducing harmful effects of unregulated cell proliferation.
Solution Approach 2:
The invention creates composite molecular structures combining multiple functional moieties (e.g., heteroaromatic rings, carbonyl groups, amino groups) into unified compounds that simultaneously target Aurora kinase activity. These composite structures enable multi-point binding to the kinase, enhancing inhibitory efficacy and improving overall treatment reliability.
2Productivity
If Aurora kinase inhibitors are developed, then cell proliferation can be arrested, but new compounds must be synthesized and tested
Solution Approach 1:
The patent divides the inhibitor molecule into distinct functional segments: heteroaromatic core structures, substituent groups, and linkage moieties. This segmentation allows independent optimization of each component's contribution to binding affinity and selectivity, simplifying the design process while maintaining high productivity in arresting cell cycling.
Solution Approach 2:
The invention develops a universal scaffold of heteroaromatic compounds that can be adapted to target different Aurora kinase members (Aurora A, B, and C) through systematic substitution patterns. This multi-functional approach enables a single compound class to address various cancer types with Aurora kinase overexpression, reducing the need for entirely new compound designs for each indication.
Data Source
AI summary
The present invention relates to chemical compounds having a general formula (I) wherein A1-5 and 7-8, D', L1, L2, R1, R3, R6-8, n and o are defined herein, and synthetic intermediates, which are capable of modulating the activity of Aurora kinase proteins and, thereby, influencing various disease states and conditions related to the activities of Aurora kinases. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.